We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1851
Triumph Financial Inc
TFIN
$1.8B
| $312K | ﹤0.01% |
4,985
-2,235
| -31% | -$158K |
|
1852
Trustmark
TRMK
$2.75B
| $312K | ﹤0.01% |
10,850
+2,059
| +23% | +$59.5K |
|
1853
Liberty Broadband Class C
LBRDK
$5.18B
| $311K | ﹤0.01% |
2,739
-2,684
| -49% | -$327K |
|
|
CASA
1854
DELISTED
Casa Systems, Inc. Common Stock
CASA
| $311K | ﹤0.01% |
79,096
-99,940
| -56% | -$435K |
|
|
TDAY
1855
USA Today Co
TDAY
$1.05B
| $310K | ﹤0.01% |
106,960
-21,935
| -17% | -$83.4K |
|
1856
ICF International
ICFI
$1.66B
| $310K | ﹤0.01% |
3,260
+173
| +6% | +$16.8K |
|
1857
Yext
YEXT
$577M
| $310K | ﹤0.01% |
64,915
-113,463
| -64% | -$630K |
|
|
ALTR
1858
DELISTED
Altair Engineering Inc
ALTR
| $310K | ﹤0.01% |
5,901
+169
| +3% | +$9.24K |
|
1859
LCI Industries
LCII
$2.55B
| $309K | ﹤0.01% |
2,762
-2,100
| -43% | -$230K |
|
1860
Sutro Biopharma
STRO
$423M
| $309K | ﹤0.01% |
5,940
+3,622
| +156% | +$202K |
|
|
JBTM
1861
JBT Marel
JBTM
$6.35B
| $309K | ﹤0.01% |
2,798
-2,335
| -45% | -$268K |
|
1862
Tenaris
TS
$27.4B
| $308K | ﹤0.01% |
12,001
-728
| -6% | -$22.4K |
|
1863
Compañía de Cervecerías Unidas
CCU
$2.24B
| $307K | ﹤0.01% |
24,341
-171,336
| -88% | -$2.33M |
|
1864
Clearfield
CLFD
$391M
| $307K | ﹤0.01% |
4,959
+281
| +6% | +$16.5K |
|
1865
Transocean
RIG
$6.33B
| $307K | ﹤0.01% |
92,174
+78,176
| +558% | +$317K |
|
1866
Akebia Therapeutics
AKBA
$234M
| $304K | ﹤0.01% |
862,168
+677,703
| +367% | +$284K |
|
1867
Interface
TILE
$2.18B
| $304K | ﹤0.01% |
24,213
-613
| -2% | -$8.13K |
|
1868
Hydrofarm Holdings
HYFM
$9.29M
| $301K | ﹤0.01% |
+8,636
| New | +$703K |
|
1869
Curis
CRIS
$7.13M
| $298K | ﹤0.01% |
757
+723
| +2,126% | +$302K |
|
1870
Hecla Mining
HL
$11.8B
| $294K | ﹤0.01% |
74,875
-191,174
| -72% | -$994K |
|
1871
Mativ Holdings
MATV
$706M
| $293K | ﹤0.01% |
+11,667
| New | +$308K |
|
1872
Rapid7
RPD
$776M
| $291K | ﹤0.01% |
4,362
+1,810
| +71% | +$150K |
|
1873
Q2 Holdings
QTWO
$3.96B
| $290K | ﹤0.01% |
7,514
-1,401
| -16% | -$68.1K |
|
1874
Olema Pharmaceuticals
OLMA
$1.04B
| $289K | ﹤0.01% |
70,973
+29,457
| +71% | +$93.4K |
|
1875
Ezcorp Inc
EZPW
$1.67B
| $288K | ﹤0.01% |
38,298
+141
| +0.4% | +$1.03K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.